Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy

Supporting evidence

• Evaluation report

• Draft guidance consultation committee papers (PDF 9.71 MB)

  Published:

  29 July 2024

• Final draft guidance committee papers (PDF 2.58 MB)

  Published:

  29 July 2024